**Breaking News!  China’s Cancer Drug Outperforms Global PD-1 Inhibitor!**

**Breaking News!  China’s Cancer Drug Outperforms Global PD-1 Inhibitor!**

PD1

#AK112 #CancerDrug #PD-1 #PD1Inhibitor #CancerTreatment #BispecificAntibody #NSCLC

China’s pharmaceutical industry has reached a historic milestone! Remember AK112 (Ivonescimab), which took center stage during this year’s ASCO conference, attracting global attention for its groundbreaking potential? The long wait is finally over, and the results are in!

In May, Akeso Biopharma, a leading Chinese pharmaceutical company, announced that its independently developed bispecific antibody drug AK112 achieved a major milestone in clinical trials. AK112 demonstrated superior efficacy to the globally renowned PD-1 inhibitor Keytruda (K Drug) in treating PD-L1-positive non-small cell lung cancer (NSCLC), marking a revolutionary breakthrough for China’s innovative cancer treatments.

**Clinical Data that Surprised the World**

During the World Conference on Lung Cancer 2024, Professor Zhou Caicun, one of China’s top lung cancer experts, revealed the results of the HARMONi-2 study, which had the entire audience applauding. The data exceeded expectations, demonstrating that AK112 is not just on par with but superior to international “superstar” cancer drugs in several key areas.

– **Progression-Free Survival (PFS):** AK112 improved PFS by an astonishing 91.4% compared to Keytruda, reaching 11.14 months versus 5.82 months.

– **Risk Reduction:** AK112 reduced the risk of disease progression or death by 49%.

– **Objective Response Rate (ORR):** AK112 outperformed Keytruda with a response rate of 50.0% compared to 38.5%.

– **Disease Control Rate (DCR):** AK112 maintained a significant advantage, achieving 89.9% versus 70.5%.

While AK112 showed slightly higher Grade 3 side effects due to its VEGF inhibition, its overall performance remains remarkable. Although overall survival (OS) data is still maturing, AK112’s impressive PFS results suggest that its survival benefits will likely be just as extraordinary.

**The Power of Bispecific Antibodies**

AK112 is part of a new class of cancer drugs called bispecific antibodies, capable of targeting two different antigens at once. In this case, AK112 targets both PD-1 and VEGF, two well-known lung cancer markers. This dual-target approach offers patients better therapeutic options and increased convenience, potentially replacing the traditional combination of PD-1 inhibitors with anti-angiogenic drugs like Avastin.

This breakthrough has made AK112 the first and only bispecific antibody drug to outperform Keytruda in head-to-head clinical trials, solidifying its place as a future game-changer in cancer treatment.

**A Milestone for China’s Pharma Industry**

In May 2024, AK112 received regulatory approval from China’s National Medical Products Administration (NMPA) for treating EGFR-mutated, locally advanced, or metastatic NSCLC, becoming the world’s first approved PD-1/VEGF bispecific antibody.

This marks a monumental achievement for China’s pharmaceutical innovation. AK112’s success demonstrates that Chinese researchers and drug developers, in just two decades, have achieved what took developed nations over a century. China’s presence at top-tier global cancer conferences like ASCO and ESMO has never been stronger, with clinical data that leaves the world in awe.

China’s pharmaceutical industry may have started late, but its rapid progress is a testament to the ingenuity and hard work of its researchers. Once relying on generics, China is now a leader in pharmaceutical innovation, offering cutting-edge treatments to patients around the globe. The future of cancer treatment is here, and it’s painted in the bold color of “China Red.”

🎉🎉To assess whether the condition is suitable for CAR-T or clinic therapy, you can submit Advanced Medicine in China  for preliminary evaluation!

WhatsApp: +8613717959070

Https://wa.me/+8613717959070

Email: doctor.huang@globecancer.com

#CancerTreatment #MedicalInnovation #PharmaBreakthrough #ChinaPharma #AK112 #LungCancer #BispecificAntibody #PD1Inhibitor #GlobalHealth #MedicalAdvancements #ProudlyMadeInChina #WorldClass

Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 78

Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 79

1 month ago Leukemia

Real-World Performance of China’s Anti-Cancer Drug Zanubrutinib in CLL/SLL Treatment: Efficacy and Safety

**Real-World Performance of China’s Anti-Cancer Drug Zanubrutinib in CLL/SLL Treatment: Efficacy and Safety**

CLL

#Ibrutinib #Zanubrutinib #CLL #SLL #BTKinhibitor #Oncology #cancerdrug #BTK #ASCO

With the advent of BTK inhibitors, the treatment paradigm for chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) has undergone a complete transformation, moving away from traditional chemotherapy. Zanubrutinib, a powerful BTK inhibitor developed independently by BeiGene in China, is a next-generation Bruton’s tyrosine kinase inhibitor (BTKi) that has demonstrated remarkable efficacy in clinical trials. A study presented at the 2024 ASCO conference sheds light on the real-world treatment patterns and outcomes of zanubrutinib, providing valuable insights for patients and clinicians.

### **Study Background**

Zanubrutinib, a fully China-developed anti-cancer drug, launched in late 2019, has been shown to be more effective than the first-generation BTKi, ibrutinib, in CLL/SLL patients. This retrospective study analyzed patients treated with zanubrutinib between 2018 and 2023 at Kaiser Permanente Northern California, focusing on treatment patterns, adverse events (AEs), and survival outcomes in a real-world setting.

### **Study Findings**

The study analyzed 281 patients with key findings as follows:

– **Patient Profile**: The median age of patients was 71 years, with 64% being male. Most patients were white (75%), followed by African Americans (10%). Of the total, 190 patients switched from ibrutinib to zanubrutinib, while 91 patients were treated solely with zanubrutinib.

– **Adverse Events**: Whether patients switched from ibrutinib or started directly on zanubrutinib, the latter showed significantly lower rates of cardiac toxicity and treatment-limiting adverse events (TLAEs). The most common AEs for zanubrutinib included cytopenia and rashes/bruising, while ibrutinib was more often associated with atrial fibrillation and fatigue.

– **Dose Adjustments and Treatment Continuity**: Some patients adjusted their doses due to mild AEs, but the majority (79%) were still receiving zanubrutinib at the end of the study. While 13 patients died, there were no treatment-related deaths.

### **Study Conclusion**

This study demonstrates that regardless of prior ibrutinib use, China’s homegrown anti-cancer drug, zanubrutinib, exhibited excellent efficacy and safety. Compared to ibrutinib, zanubrutinib had a lower incidence of cardiac toxicity and maintained its effectiveness even in older patients with more comorbidities. These real-world data reinforce zanubrutinib’s pivotal role in the treatment of CLL/SLL, further validating its clinical application.

🎉🎉To assess whether the condition is suitable for CAR-T or clinic therapy, you can submit Advanced Medicine in China  for preliminary evaluation!

WhatsApp: +8613717959070

Https://wa.me/+8613717959070

Email: doctor.huang@globecancer.com

#CancerTreatment #RealWorldData #CancerResearch #BeiGene #ASCO2024